Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years.~* Voluntary signed informed consent (IC)~* Pathologically proven diagnosis of any of the following malignancies:~  * Small cell lung cancer (SCLC).~ * Head and neck carcinoma (H\&N). Salivary glands tumors are excluded.~ * Neuroendocrine tumors (NETs), grade 2 and grade 3 according to World Health Organization classification.~ * Biliary tract carcinoma.~ * Endometrial carcinoma.~ * BRCA 1/2- associated metastatic breast carcinoma~ * Carcinoma of unknown primary site.~ * Germ cell tumor (GCTs), excluding immature teratoma, or teratoma with malignant transformation.~ * Ewing's family of tumors (EFTs)~* Prior treatment. Patients must have received:~  * SCLC, endometrial carcinoma: one prior chemotherapy-containing line.~ * H\&N, NETs, biliary tract, CUP: one or two prior chemotherapy-containing lines~ * GCTs: no limit of prior therapy~ * EFTs: no more than two prior chemotherapy-containing lines in the metastatic/recurrent setting.~ * BRCA 1/2-associated metastatic breast carcinoma: at least one but no more than three prior chemotherapy-containing lines.~* Performance status ≤ 2 \[Eastern Cooperative Oncology Group (ECOG)\]~* Adequate major organ function~* At least three weeks since the last chemotherapy~* Women of childbearing potential must have pregnancy excluded by appropriate testing before study entry~Exclusion Criteria:~* Prior treatment with PM01183 or trabectedin~* Prior or concurrent malignant disease unless in complete remission for more than five years~* Known central nervous system (CNS) involvement~* Relevant diseases or clinical situations which may increase the patient's risk~* Pregnant or breastfeeding women and fertile patients (men and women) who are not using an effective method of contraception

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- lurbinectedin (PM01183) (Type: EXPERIMENTAL): lurbinectedin (PM01183) 4 mg vials of powder for concentrate for solution for infusion

Based on this trial design, predict the completion outcome and termination type (if applicable).